Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide - Nauck, Michael A.; Frossard, Jean-Louis; Barkin, Jamie S.; Anglin, Greg; Hensley, Ingrid E.; Harper, Kristine D.; Milicevic, Zvonko (Diabetes care, 2017)
Keywords: Acute Disease; Adjudication; Amylases; Antidiabetics; Clinical trials; Comparators; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - drug therapy; Enzymes; Etiology; Exposure; Female; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide-1 Receptor - agonists; Glucagon-Like Peptides - adverse effects; Glucagon-Like Peptides - analogs & derivatives; Glucagon-Like Peptides - therapeutic use; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Immunoglobulin Fc Fragments - adverse effects; Immunoglobulin Fc Fragments - therapeutic use; Incidence; Insulin; Insulin Glargine - adverse effects; Insulin Glargine - therapeutic use; Lipase; Male; Medical treatment; Metformin; Metformin - adverse effects; Metformin - therapeutic use; Middle Aged; Pain; Pancreas; Pancreatitis; Pancreatitis - chemically induced; Patients; Peptides; Peptides - adverse effects; Peptides - therapeutic use; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - therapeutic use; Research design; Risk assessment; Sitagliptin Phosphate - adverse effects; Sitagliptin Phosphate - therapeutic use; Venoms - adverse effects; Venoms - therapeutic use